Shannon Kelley Sells 360 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) General Counsel Shannon Kelley sold 360 shares of the firm’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $431.94, for a total transaction of $155,498.40. Following the sale, the general counsel owned 12,138 shares in the company, valued at approximately $5,242,887.72. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Madrigal Pharmaceuticals Trading Down 1.5%

MDGL opened at $432.83 on Friday. The stock has a market capitalization of $9.93 billion, a P/E ratio of -33.63 and a beta of -0.97. The company has a current ratio of 4.01, a quick ratio of 3.77 and a debt-to-equity ratio of 0.56. Madrigal Pharmaceuticals, Inc. has a 12 month low of $265.00 and a 12 month high of $615.00. The firm’s fifty day simple moving average is $492.64 and its 200 day simple moving average is $487.47.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($2.61). Madrigal Pharmaceuticals had a negative return on equity of 43.76% and a negative net margin of 30.08%.The firm had revenue of $321.08 million for the quarter, compared to the consensus estimate of $310.36 million. During the same quarter last year, the company posted ($2.71) EPS. Madrigal Pharmaceuticals’s revenue for the quarter was up 210.8% on a year-over-year basis. As a group, research analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. HC Wainwright lifted their target price on Madrigal Pharmaceuticals from $568.00 to $620.00 and gave the company a “buy” rating in a research report on Friday, November 21st. UBS Group set a $900.00 price target on Madrigal Pharmaceuticals in a research report on Friday, December 19th. Barclays began coverage on shares of Madrigal Pharmaceuticals in a research note on Tuesday, January 27th. They set an “overweight” rating and a $964.00 price target for the company. Citigroup reiterated an “outperform” rating on shares of Madrigal Pharmaceuticals in a report on Tuesday, January 20th. Finally, B. Riley Financial boosted their price objective on shares of Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $685.31.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Groupama Asset Managment raised its stake in shares of Madrigal Pharmaceuticals by 11.6% during the 4th quarter. Groupama Asset Managment now owns 30,620 shares of the biopharmaceutical company’s stock worth $17,831,000 after purchasing an additional 3,176 shares in the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Madrigal Pharmaceuticals in the 4th quarter valued at approximately $1,083,000. Invesco Ltd. grew its stake in shares of Madrigal Pharmaceuticals by 21.9% in the fourth quarter. Invesco Ltd. now owns 365,314 shares of the biopharmaceutical company’s stock valued at $212,737,000 after buying an additional 65,749 shares in the last quarter. EP Wealth Advisors LLC bought a new position in shares of Madrigal Pharmaceuticals in the fourth quarter valued at $355,000. Finally, XTX Topco Ltd acquired a new position in Madrigal Pharmaceuticals during the fourth quarter worth $1,642,000. 98.50% of the stock is currently owned by institutional investors.

More Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Company granted inducement equity awards to 20 new non‑executive hires under Nasdaq Rule 5635(c)(4), which can help recruit talent and support execution of the pipeline programs. Madrigal Announces Grants of Inducement Awards
• Neutral Sentiment: All insider trades were formally reported via SEC Form 4 filings (standard disclosure), so the transactions are public and fully documented. Example SEC Form 4 Filing
• Negative Sentiment: CEO William John Sibold sold 1,663 shares (~$718k); his holdings fell ~1.02% after the sale. CEO Form 4
• Negative Sentiment: CFO Mardi Dier sold 1,982 shares (~$854k); this represented a ~13.7% reduction in her ownership. Large percentage cuts by the CFO can be read as a stronger negative signal. CFO Form 4
• Negative Sentiment: General Counsel Shannon T. Kelley sold 360 shares (~$155k), a ~2.88% position reduction. GC Form 4
• Negative Sentiment: Director Rebecca Taub sold 491 shares (~$212k); she still retains a large stake (~452k shares) but reduced ownership slightly. Director Form 4
• Negative Sentiment: Insider Carole Huntsman sold 419 shares (~$181k), a ~3.20% decrease in her holding. Insider Form 4

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.